Porter Hospital Turns into First Facility in Denver to Give Power Low Again Ache Sufferers Entry to Revolutionary Nociscan Know-how That Measures Biomarkers to Pinpoint the Supply of Ache
George Frey, MD Turns into Aclarion’s First KOL Surgeon to Onboard a Hospital MRI so as to add Nociscan Knowledge to his Remedy Decisioning Course of for Power Low Again Ache Sufferers
Printed Medical Knowledge Demonstrates That Affected person Outcomes are Improved and Prices are Lowered When Surgical Remedy is Constant With the Disc Ranges Nociscan Identifies as Painful
BROOMFIELD, CO, Oct. 25, 2023 (GLOBE NEWSWIRE) — by way of NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Firm”) (Nasdaq: ACON, ACONW), a healthcare know-how firm that’s leveraging biomarkers and proprietary augmented intelligence algorithms to assist physicians determine the placement of continual low again ache, introduced at the moment their expanded footprint in Colorado with AdventHealth Porter. From their location in Denver, AdventHealth Porter offers distinctive medical care to sufferers all through the entrance vary of Colorado.
George Frey MD, Orthopedic Surgeon and founding father of the Colorado Complete Backbone Institute stated, “Treating sufferers successfully begins with an knowledgeable understanding of the place their ache is coming from. In my expertise with Nociscan, objectively measuring the biomarker content material corelated with ache inside a disc that will look wholesome on an MRI, provides to my information of how you can deal with that affected person. At AdventHealth Porter, we’re dedicated to offer the best high quality price efficient care potential. The revealed proof is obvious to me that including Nociscan to our diagnostic analysis could assist us try this.”
Brent Ness, CEO of Aclarion, stated, “In step with our technique to drive Nociscan to straightforward of care by means of KOL advocacy, we applaud AdventHealth Porter in bringing Nociscan know-how to Denver in help of Dr. Frey’s imaginative and prescient to make the most of our know-how to enhance outcomes whereas decreasing prices. The help of pioneering leaders like Dr. Frey and AdventHealth is strictly the management we have to unequivocally exhibit the superior scientific outcomes for sufferers that may drive protection selections by payers and provides all sufferers entry to Nociscan know-how. We thank Dr. Frey and AdventHealth and stay up for the constructive impression growing Nociscan volumes can have on the surgical outcomes of continual low again sufferers in and across the Denver group.”
“Offering distinctive care with modern remedies is a core worth of our multidiscipline healthcare staff right here at AdventHealth Porter,” said Carol Bermingham, Imaging Supervisor at AdventHealth Porter. “We’re smitten by including Nociscan to our MRI functionality and imagine offering personalised biomarker information to treating physicians is yet one more funding in our dedication to offering an atmosphere the place our docs can do their best for his or her sufferers. Our radiology service line is at all times striving to remain on the entrance fringe of the technical development curve.”
Power low again ache (cLBP) is a worldwide healthcare downside, with roughly 266 million folks worldwide affected by degenerative spine illness and low again ache. Low again ache has been estimated to have an effect on as much as 30 million adults within the US inhabitants every year, resulting in thousands and thousands of doctor consults per yr.
Aclarion’s proprietary decision-support instrument, Nociscan, is the primary evidence-supported SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be related to disc ache. Biomarker information is entered into proprietary algorithms to focus on if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan offers crucial insights into the placement of a affected person’s low again ache, giving physicians readability to optimize therapy methods.
About Aclarion, Inc.
Aclarion is a healthcare know-how firm that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary sign processing strategies, biomarkers, and augmented intelligence algorithms to optimize scientific remedies. The Firm is first addressing the continual low again ache market with Nociscan, the primary, evidence-supported, SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. Via a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) information from an MRI machine for every lumbar disc being evaluated. Within the cloud, proprietary sign processing strategies extract and quantify chemical biomarkers demonstrated to be related to disc ache. Biomarker information is entered into proprietary algorithms to point if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan offers crucial insights into the placement of a affected person’s low again ache, giving physicians readability to optimize therapy methods. For extra data, please go to www.aclarion.com.
Ahead Wanting Statements
This press launch comprises forward-looking statements throughout the which means of the Personal Securities Litigation Reform Act of 1995, Part 27A of the Securities Act of 1933 and Part 21E of the Securities Trade Act of 1934 concerning the Firm’s present expectations about future outcomes, efficiency, prospects and alternatives. Statements that aren’t historic information, resembling “anticipates,” “believes” and “expects” or comparable expressions, are forward-looking statements. These forward-looking statements are primarily based on the present plans and expectations of administration and are topic to a variety of uncertainties and dangers that might considerably have an effect on the Firm’s present plans and expectations, in addition to future outcomes of operations and monetary situation. These and different dangers and uncertainties are mentioned extra totally in our filings with the Securities and Trade Fee. Readers are inspired to evaluate the part titled “Danger Elements” within the Firm’s Prospectus dated April 21, 2022, as filed with the Securities and Trade Fee on April 25, 2022 below Rule 424(b)(4), in addition to different disclosures contained within the Prospectus and subsequent filings made with the Securities and Trade Fee. Ahead-looking statements contained on this announcement are made as of this date and the Firm undertakes no obligation to publicly replace or revise any forward-looking statements, whether or not on account of new data, future occasions or in any other case.
Kirin M. Smith
PCG Advisory, Inc.